EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
August 29, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Announces Enrollment of First Patient in PRK Pilot Study
August 20, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
August 07, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
August 03, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel
July 24, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
FDA Grants Approval for Studies for Patients that have undergone Photorefractive Keratectomy and for Patients with Punctate Epitheliopathies WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) --...
EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel
June 22, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
Responses to the last of four outstanding action items submitted; Potential to start clinical study in the Third Quarter of 2018 WALTHAM, Mass., June 22, 2018 (GLOBE NEWSWIRE) -- EyeGate...
EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel
May 30, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel
May 22, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
Responses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to start clinical study in the Third Quarter of...
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
May 16, 2018 16:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
May 11, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...